Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Psychoneuroendocrinology. 2014 Oct 7;51:495–505. doi: 10.1016/j.psyneuen.2014.09.030

Figure 2.

Figure 2

(A) % acquisition response retained across the extinction phase by symptom group. *p < .05 for PTSD symptoms vs. healthy comparison. #p < .05 for exploratory comparisons vs. healthy controls. (B) CS+ expectancy ratings across the entire extinction phase. Ratings have been combined into 4-trial blocks for clarity. (C) Self-reported anxiety following the acquisition and extinction phases by symptom group. *p < .05 for comparisons across phase and for the anxiety symptoms vs. healthy comparison. #p < .05 for PTSD and anxiety symptoms vs. healthy comparisons within the extinction phase.